Literature DB >> 20588163

Increased levels of immune activation in the genital tract of healthy young women from sub-Saharan Africa.

Craig R Cohen1, Anna-Barbara Moscicki, Mark E Scott, Yifei Ma, Stephen Shiboski, Elizabeth Bukusi, Ibrahim Daud, Anu Rebbapragada, Joelle Brown, Rupert Kaul.   

Abstract

OBJECTIVES: To determine whether healthy, young women in sub-Saharan Africa have a more activated immune milieu in the genital tract (i.e. activated CD4 T cells) than a similar population in the United States.
DESIGN: A cross-sectional study nested in a phase 1 microbicide trial.
METHODS: Cervical cytobrushes were collected from 18 to 24-year-old women in San Francisco, California, USA (n = 18) and Kisumu, Kenya (n = 36) at enrollment into a phase 1 microbicide trial. All participants tested negative for HIV, herpes simplex virus 2, gonorrhea, chlamydia, and trichomonas, and had abstained from sex for at least 7 days prior to enrollment. Cryopreserved T-cell populations were assayed by flow cytometry in a central laboratory. Secretory leukocyte protease inhibitor levels were assayed in cervicovaginal lavage samples. The Wilcoxon rank-sum test was used to compare immune parameters between sites.
RESULTS: The total number of endocervical CD4(+) T cells was slightly higher in participants from San Francisco, but participants from Kisumu had a substantially higher number and proportion of CD4(+) T cells expressing the early activation marker CD69, with and without the HIV coreceptor C-C chemokine receptor type 5, and a greater proportion of activated CD8(+) T cells. Median (interquartile range) genital levels of secretory leukocyte protease inhibitor were lower in participants from Kisumu compared with those from San Francisco [190 (96-519) vs. 474 (206 817) pg/ml, P < 0.03].
CONCLUSION: Activated mucosal T cells were increased in the genital tract of young, sexually transmitted infection/HIV-free Kenyan women, independent of common genital coinfections, and secretory leukocyte protease inhibitor levels were reduced. The cause of these mucosal immune differences is not known, but could partly explain the high HIV incidence in young women from sub-Saharan Africa.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20588163      PMCID: PMC2914808          DOI: 10.1097/QAD.0b013e32833c323b

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  24 in total

1.  Improved amplification of genital human papillomaviruses.

Authors:  P E Gravitt; C L Peyton; T Q Alessi; C M Wheeler; F Coutlée; A Hildesheim; M H Schiffman; D R Scott; R J Apple
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

2.  Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females.

Authors:  A B Moscicki; N Hills; S Shiboski; K Powell; N Jay; E Hanson; S Miller; L Clayton; S Farhat; J Broering; T Darragh; J Palefsky
Journal:  JAMA       Date:  2001-06-20       Impact factor: 56.272

3.  The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission.

Authors:  R N Fichorova; L D Tucker; D J Anderson
Journal:  J Infect Dis       Date:  2001-07-16       Impact factor: 5.226

4.  Hormonal contraception and the risk of HIV acquisition.

Authors:  Charles S Morrison; Barbra A Richardson; Francis Mmiro; Tsungai Chipato; David D Celentano; Joanne Luoto; Roy Mugerwa; Nancy Padian; Sungwal Rugpao; Joelle M Brown; Peter Cornelisse; Robert A Salata
Journal:  AIDS       Date:  2007-01-02       Impact factor: 4.177

5.  Increased interleukin-10 in the the endocervical secretions of women with non-ulcerative sexually transmitted diseases: a mechanism for enhanced HIV-1 transmission?

Authors:  C R Cohen; F A Plummer; N Mugo; I Maclean; C Shen; E A Bukusi; E Irungu; S Sinei; J Bwayo; R C Brunham
Journal:  AIDS       Date:  1999-02-25       Impact factor: 4.177

6.  A preponderance of CCR5(+) CXCR4(+) mononuclear cells enhances gastrointestinal mucosal susceptibility to human immunodeficiency virus type 1 infection.

Authors:  M A Poles; J Elliott; P Taing; P A Anton; I S Chen
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

7.  Immune activation in africa is environmentally-driven and is associated with upregulation of CCR5. Italian-Ugandan AIDS Project.

Authors:  M Clerici; S Butto; M Lukwiya; M Saresella; S Declich; D Trabattoni; C Pastori; S Piconi; C Fracasso; M Fabiani; P Ferrante; G Rizzardini; L Lopalco
Journal:  AIDS       Date:  2000-09-29       Impact factor: 4.177

8.  Early age of first sex: a risk factor for HIV infection among women in Zimbabwe.

Authors:  Audrey E Pettifor; Ariane van der Straten; Megan S Dunbar; Stephen C Shiboski; Nancy S Padian
Journal:  AIDS       Date:  2004-07-02       Impact factor: 4.177

9.  Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro.

Authors:  T B McNeely; M Dealy; D J Dripps; J M Orenstein; S P Eisenberg; S M Wahl
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

10.  Susceptibility to human immunodeficiency virus-1 infection of human foreskin and cervical tissue grown in explant culture.

Authors:  Bruce K Patterson; Alan Landay; Joan N Siegel; Zareefa Flener; Dennis Pessis; Antonio Chaviano; Robert C Bailey
Journal:  Am J Pathol       Date:  2002-09       Impact factor: 4.307

View more
  38 in total

1.  Measurement of mucosal biomarkers in a phase 1 trial of intravaginal 3% StarPharma LTD 7013 gel (VivaGel) to assess expanded safety.

Authors:  Anna-Barbara Moscicki; Rupert Kaul; Yifei Ma; Mark E Scott; Ibrahim I Daud; Elizabeth A Bukusi; Stephen Shiboski; Anuradha Rebbapragada; Sanja Huibner; Craig R Cohen
Journal:  J Acquir Immune Defic Syndr       Date:  2012-02-01       Impact factor: 3.731

2.  Secretory leukocyte protease inhibitor binds to Neisseria gonorrhoeae outer membrane opacity protein and is bactericidal.

Authors:  Morris D Cooper; Melissa H Roberts; Ona L Barauskas; Gary A Jarvis
Journal:  Am J Reprod Immunol       Date:  2012-04-26       Impact factor: 3.886

Review 3.  Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development.

Authors:  Joshua T Schiffer; Sami L Gottlieb
Journal:  Vaccine       Date:  2017-09-25       Impact factor: 3.641

4.  Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.

Authors:  Glenda E Gray; Zoe Moodie; Barbara Metch; Peter B Gilbert; Linda-Gail Bekker; Gavin Churchyard; Maphoshane Nchabeleng; Koleka Mlisana; Fatima Laher; Surita Roux; Kathryn Mngadi; Craig Innes; Matsontso Mathebula; Mary Allen; M Julie McElrath; Michael Robertson; James Kublin; Lawrence Corey
Journal:  Lancet Infect Dis       Date:  2014-02-20       Impact factor: 25.071

Review 5.  Inflammation and HIV Transmission in Sub-Saharan Africa.

Authors:  Rupert Kaul; Jessica Prodger; Vineet Joag; Brett Shannon; Sergey Yegorov; Ronald Galiwango; Lyle McKinnon
Journal:  Curr HIV/AIDS Rep       Date:  2015-06       Impact factor: 5.071

6.  Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract.

Authors:  Melis N Anahtar; Elizabeth H Byrne; Kathleen E Doherty; Brittany A Bowman; Hidemi S Yamamoto; Magali Soumillon; Nikita Padavattan; Nasreen Ismail; Amber Moodley; Mary E Sabatini; Musie S Ghebremichael; Chad Nusbaum; Curtis Huttenhower; Herbert W Virgin; Thumbi Ndung'u; Krista L Dong; Bruce D Walker; Raina N Fichorova; Douglas S Kwon
Journal:  Immunity       Date:  2015-05-19       Impact factor: 31.745

7.  Immune activation in the female genital tract during HIV infection predicts mucosal CD4 depletion and HIV shedding.

Authors:  Heather B Jaspan; Lenine Liebenberg; Willem Hanekom; Wendy Burgers; David Coetzee; Anna-Lise Williamson; Francesca Little; Landon Myer; Robert W Coombs; Don Sodora; Jo-Ann Passmore
Journal:  J Infect Dis       Date:  2011-09-21       Impact factor: 5.226

8.  Semen protects CD4+ target cells from HIV infection but promotes the preferential transmission of R5 tropic HIV.

Authors:  Emmanuel Balandya; Siddharth Sheth; Katherine Sanders; Wendy Wieland-Alter; Timothy Lahey
Journal:  J Immunol       Date:  2010-11-08       Impact factor: 5.422

9.  Evaluation of PD 404,182 as an anti-HIV and anti-herpes simplex virus microbicide.

Authors:  Ana M Chamoun-Emanuelli; Michael Bobardt; Bernard Moncla; Marie K Mankowski; Roger G Ptak; Philippe Gallay; Zhilei Chen
Journal:  Antimicrob Agents Chemother       Date:  2013-11-11       Impact factor: 5.191

10.  Reduced immune activation during tenofovir-emtricitabine therapy in HIV-negative individuals.

Authors:  Jose R Castillo-Mancilla; Amie Meditz; Cara Wilson; Jia-Hua Zheng; Brent E Palmer; Eric J Lee; Edward M Gardner; Sharon Seifert; Becky Kerr; Lane R Bushman; Samantha MaWhinney; Peter L Anderson
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-15       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.